Joseph Woodard
Direttore Tecnico/Scientifico/R&S presso IMUGENE LIMITED
Profilo
Joseph Paul Woodard is currently the Chief Medical Officer at Imugene Ltd.
He previously worked as the Senior Vice President-Clinical & Medical Affairs at Bellicum Pharmaceuticals, Inc. from 2017 to 2019.
He also served as the Chief Medical Officer & Senior Vice President at Immune-Onc Therapeutics, Inc. Dr. Woodard received his undergraduate degree from The University of North Carolina at Charlotte and his doctorate from UNC School of Medicine.
Posizioni attive di Joseph Woodard
| Società | Posizione | Inizio |
|---|---|---|
| IMUGENE LIMITED | Direttore Tecnico/Scientifico/R&S | 04/09/2023 |
Precedenti posizioni note di Joseph Woodard
| Società | Posizione | Fine |
|---|---|---|
| BELLICUM PHARMACEUTICALS, INC. | Direttore Tecnico/Scientifico/R&S | 01/11/2019 |
Immune-Onc Therapeutics, Inc.
 Immune-Onc Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Immune-Onc Therapeutics, Inc. operates as a biopharmaceutical company focused on developing innovative therapeutic antibodies for cancer treatment. The company was founded by Charlene Liao and Gui-Liang Yu in 2016 and is headquartered in Palo Alto, CA. | Direttore Tecnico/Scientifico/R&S | - |
Formazione di Joseph Woodard
| The University of North Carolina at Charlotte | Undergraduate Degree |
| UNC School of Medicine | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| IMUGENE LIMITED | Health Technology |
| Aziende private | 2 |
|---|---|
Bellicum Pharmaceuticals, Inc.
 Bellicum Pharmaceuticals, Inc. BiotechnologyHealth Technology Bellicum Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It focuses on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. The firm uses its proprietary chemical induction of dimerization that controls components of the immune system in real time. Its product candidates include BPX-601, BPX-603, and Rivo-cel (rivogenlecleucel, formerly known as BPX-501). The company was founded by Kevin M. Slawin and David M. Spencer on July 14, 2004 and is headquartered in Houston, TX. | Health Technology |
Immune-Onc Therapeutics, Inc.
Immune-Onc Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Immune-Onc Therapeutics, Inc. operates as a biopharmaceutical company focused on developing innovative therapeutic antibodies for cancer treatment. The company was founded by Charlene Liao and Gui-Liang Yu in 2016 and is headquartered in Palo Alto, CA. | Health Technology |
- Borsa valori
- Insiders
- Joseph Woodard
